Kamada Ltd. · NASDAQ:KMDA
Kamada — Q3 2026 Earnings Presentation
17 slides from Kamada's earnings presentation, Nov 9, 2026
Slide 1: Q3/2026 & 9M/2026 Investors Call
November 2026 Q3/2026 & 9M/2026 Investors Call NASDAQ: KMDA; TASE: KMDA.TA
Slide 2: Forward-Looking Statement
2 FORWARD - LOOKING STATEMENT This presentation is not intended to provide investment or medical advice . This presentation contains forward - looking statements, which express the current beliefs and expectations of Kamada ’ s management . Such statements include the 2026 financial guidance, roadma
Slide 3: Record-high nine-month results, increasing 2026 annual guidance
3 RECORD - HIGH NINE - MONTH RESULTS INCREASING 2026 ANNUAL GUIDANCE EXECUTING ON OUR PLAN PROJECTING DOUBLE - DIGIT PROFITABLE GROWTH FOR FY 2027
Slide 4: 9M-2026 delivering record-high results
4 9 M - 2026 DELIVERING RECORD - HIGH RESULTS YoY DOUBLE DIGIT REVENUE AND PROFITABLE INCREASE Adj. EBITDA REVENUE 20% 2025 $34.2 2026 $ 40.9 12% 2025 $135.8 2026 $ 152.2 Operating Cash Flow EPS č 10 % 2025 $17.9 2026 $ 37.6 28% 2025 $0.29 2026 $0.37 Declared cash dividend of $0.14 per share (approx
Slide 5: Delivering annual double-digit profitable growth
5 DELIVERING ANNUAL DOUBLE - DIGIT PROFITABLE GROWTH 6 6 % 18 14% 24 17% 34 21% 42 23 % 52 - 54 ~26% 2021 2022 2023 2024 2025 2026 104 129 142 161 180 205 - 208 2021 2022 2023 2024 2025 2026 ADJUSTED EBITDA US$M 53 % CAGR 2026 represents annual guidance; 9M/26 actual performance 2026 represents annu
Slide 6: Kamada's growth drivers
6 KAMADA ’ S GROWTH DRIVERS Specialty Plasma Therapies Portfolio of 6 FDA - approved products marketed in over 30 territories In - licensing Partnerships Commercialization & Distribution of third parties ’ biopharmaceutical products in Israel & MENA Plasma Sales Secured a 3 - year app . $ 50 M plasm
Slide 7: FDA-approved specialty plasma products
7 6 FDA - APPROVED SPECIALTY PLASMA PRODUCTS KEY FOCUS ON TRANSPLANTS & RARE CONDITIONS For Important Safety Information, visit www.Kamada.com CYTOGAM® [Cytomegalovirus Immune Globulin (Human)] Prophylaxis of CMV disease associated with transplants GLASSIA® [Alpha 1 - Proteinase Inhibitor (Human)] A
Slide 8: Distribution segment growth
8 DISTRIBUTION SEGMENT GROWTH More than 25 products exclusively licensed from leading international pharmaceutical companies, marketed in the Israeli market EXCLUSIVE DISTRIBUTOR IN ISRAEL & MENA FOR BIOPHARMACEUTICAL COMPANIES Key areas : plasma - derived, respiratory, rare diseases, infectious dis
Slide 9: Kamada Plasma expanding vertical integration
9 KAMADA PLASMA EXPANDING VERTICAL INTEGRATION & REVENUE GROWTH Collecting hyper - immune plasma for our specialty IgG products and normal source plasma (NSP) to support revenue growth Operating three FDA Approved plasma collection centers in Texas; Houston, San Antonio and Beaumont In July 2026 ann
Slide 10: M&A transactions
10 M&A TRANSACTIONS AIMING TO SECURE NEW BUSINESS DEVELOPMENT AND M&A TRANSACTIONS LEVERAGING OVERALL FINANCIAL STRENGTH AND COMMERCIAL INFRASTRUCTURE Screening strategic business development opportunities to identify potential acquisition or in - licensing to accelerate long - term growth Focusing
Slide 11: Record-high 9M-26 financial results details
11 1. Adjusted EBITDA is defined as net income, plus ( i ) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (iv) non - cash share - based compensation expenses RECORD - HIGH 9 M - 26 FINANCIAL RESULTS DETAILS FY/2025 Q 3 / 25 Q3/26 9 M/ 25 9M/26 US $ M Dri
Slide 12: Kamada - a global biopharmaceutical company
KEDRAB® CYTOGAM® HEPAGAM B® VARIZIG® WINRHO® GLASSIA® KAMADA - A GLOBAL BIOPHARMACEUTICAL COMPANY 6 FDA - Approved Products 14 % CAGR (from 2021) $ 205 - 208 M 1 2026 Revenues Guidance $ 52 - 54M 1 2026 Adj. EBITDA Guidance 4 Growth Drivers A LEADER IN SPECIALTY PLASMA THERAPIES, WITH A PORTFOLIO OF
Slide 13: Thank you
THANK YOU www.kamada.com NASDAQ: KMDA; TASE: KMDA.TA
Slide 14: Non-IFRS measures – Adjusted EBITDA
14 NON - IFRS MEASURES – ADJUSTED EBITDA Adjusted EBITDA is defined as net income, plus ( i ) tax expense, (ii) financial income (expense), net, (iii) depreciation and amortization ; and (iv) non - cash share - based compensation expenses FY/2025 Q3/25 Q3/26 9M/25 9 M/ 26 US $ M 20.2 5.3 8.0 16.6 21
Slide 15: A global leader in anti-rabies immune globulin (KEDRAB)
$180M Total estimated U.S HRIG market size The only anti - Rabies IgG product with FDA approved label confirming safety and effectiveness in children KEDRAB /KAMRAB $ 54 M ( 2025 revenues) 2026 demand demonstrating continues growth year over year Only 2 FDA approved products Leading HRIG in Canada,
Slide 16: GLASSIA - liquid AAT for AAT deficiency
16 Licensed to Takeda in the USA, Canada, Australia and New Zealand Commencing in 2022 , Takeda is paying Kamada royalties, at a rate of 6 % through 2040 ; Projected royalties in the range of $ 10 M to $ 20 M per year Outside the Takeda territories, GLASSIA is marketed by Kamada through a network of
Slide 17: CYTOGAM - CMV immune globulin
17 CYTOGAM $ 17 M 2025 Revenues CMV IMMUNE GLOBULIN Sales Growth To be supported by new clinical data demonstrating product ’ s unique properties CYTOGAM is the only plasma - derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the lead